WAM
ALLO icon

Wealthspire Advisors (Maryland)’s Allogene Therapeutics ALLO Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,000
Closed -$214K – 489
2020
Q2 		$214K Buy
+5,000
New +$181K 0.02% 406

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s ALLO Position: Q3 2020 in Review

Wealthspire Advisors (Maryland) sold out of Allogene Therapeutics (ALLO) in Q3 2020, closing a stake of 5,000 shares — an estimated $214K sold.

Wealthspire Advisors (Maryland) first reported a position in ALLO in Q2 2020 and held it in 1 quarter. The position peaked at $214K in Q2 2020. 162 funds tracked by Wall St. Rank hold ALLO as of Q3 2020.

  • Wealthspire Advisors (Maryland) reported no remaining Allogene Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 5,000 Allogene Therapeutics shares in Q3 2020, an estimated $214K.
  • Wealthspire Advisors (Maryland) first reported a position in Allogene Therapeutics in Q2 2020 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s Allogene Therapeutics position peaked at $214K in Q2 2020.
  • 162 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2020.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q3 2020, filed 13 Nov 2020.